print
Lapatinib plus paclitaxel for metastatic breast cancer - first line
- Source agency:
- NHSC
- Date of Submission:
- 02/02/2010
- Date of Printing:
- 10/03/2010
- Technology name:
- Lapatinib (Tyverb(TM), GW-572016)
- Technology - type(s):
- Drug
- Patient indications:
- Breast cancer: metastatic, HER-2 (ErbB2) positive - first line; in combination with paclitaxel.